Urologists’ Views on Contact With Industry Representatives: A Pilot Survey by Zeffren, Marc et al.
Touro Scholar 
NYMC Student Posters Students 
3-6-2017 
Urologists’ Views on Contact With Industry Representatives: A 
Pilot Survey 
Marc Zeffren 
New York Medical College 
Joel Hillelsohn 
Michael Stern 
Follow this and additional works at: https://touroscholar.touro.edu/nymc_students_posters 
 Part of the Urology Commons 
Recommended Citation 
Zeffren, M., Hillelsohn, J., & Stern, M. (2017, March). Urologists’ views on contact with industry 
representatives: a pilot survey. Poster presented at the 21st annual Medical Student Research Forum, 
Valhalla, NY. 
This Poster is brought to you for free and open access by the Students at Touro Scholar. It has been accepted for 
inclusion in NYMC Student Posters by an authorized administrator of Touro Scholar. For more information, please 
contact touro.scholar@touro.edu. 
Regulations on PR 
A substantial body of research examines the nature of physician-industry relationships, with many authors concluding that 
such intimate ties invite major conflicts of interest. The most comprehensive definition for conflict of interest can be found 
in a 1993 NEJM article1: “A set of conditions in which professional judgment concerning a patient’s welfare…can be 
influenced by financial gain. Paid speaking engagements, gifts, travel, owning of company shares etc.” Conflicts of interest 
arise because physicians are the target of substantial product marketing. Doctors’ offices are inundated with drug samples, 
pens, notepads, all for purpose of creating familiarity with a drug name or device brand. Doctors also receive lunch-hour 
presentations billed as educational events aimed at teaching the group about new medications or the updated version of a 
device being introduced to market. 
Doctors feel that industry reps provide important teaching and training opportunities which would otherwise go 
unfulfilled2. Indeed, reps can have such intimate roles in patient care that a study of surgeons found that these physicians 
viewed their device reps as valuable members of the surgical team2. But research shows that despite doctors’ insistence 
otherwise, sponsored CME demonstrably leads to increases in prescription rates of the promoted medication by the 
attendant physicians3,4. In the surgical suite, it has been shown that in much the same way as regular interaction with PR 
increases the chance of a drug being added to a hospital’s formulary5, regular contact with DMR increases the likelihood 
that the devices they market will be used over a competitor’s, regardless of differences in efficacy or functionality. This 
problem is further compounded by the brand loyalty that surgeons maintain for an extended time6. This has significant 
effects on healthcare costs. One study found that up to 61% of a hospitals expenditure on surgical devices goes to 
preference items7, an area where the presence of a device rep has a substantial impact. 
Despite the amount of “education” physicians are receiving, research has also shown that having an established relationship 
with pharmaceutical representatives actually reduces rather than increases physician awareness of adverse drug effects8.  
A 2000 landmark article was published in JAMA reviewing 16 previous studies regarding these relationships, reporting 
averages of 4 monthly interactions and the receipt of 6 gifts per year from industry representatives3, either pharmaceutical 
representatives (PR), or device manufacturer representatives (DMR). Later studies showed even greater numbers of meetings 
per month with industry representatives9. Indeed these interaction are pervasive, accepted as simply part of the healthcare 
industry milieu, but the effects are undeniable, and greater awareness of them is paramount to ensuring equity in healthcare 
delivery. 
Purpose: The current survey aims to determine the various ways in which urologists at all levels of training view the nature 
of their relationships with industry representatives, and the effects these relationships may have on clinical practice and 
behavior.  
Methods: We sent an anonymous SurveyMonkey® questionnaire to a cohort of approximately 1700 practicing urologists in 
various urologic subspecialties across the country. The questionnaire elicited information related to demographics, personal 
awareness of institutional guidelines regarding PR/DMR, and opinions regarding the following: 
• the ability of industry-supplied gifts to compromise judgment 
• the utility and appropriateness of industry representatives in the clinical setting 
• the effects of governmental regulations addressing physician-industry contact 
• the effects of receipt of promotional items in influencing clinical behaviors 
• the need for laws governing physician contact with industry representatives 
Opinions were reported on 5-point Likert scales ranging from “Strongly Agree” to “Strongly Disagree” allowing the 
respondent the freedom to be “Undecided”. Finally, a free text response was made available at the end of the survey for 
comments and feedback regarding the survey. 
In the analysis phase “Strongly Agree” and “Agree” responses were pooled, as were “Strongly Disagree” and “Disagree”. 
Four respondents were excluded from the final analysis because they failed to complete the opinions sections regarding 
PR/DMR. 
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PR has no impact on my
prescribing behavior
All Respondents Residents Fellow Attending 




Complete ban: I am 
allowed no contact with PR 26 27% 3 33% 6 100% 17 39% 
Promotional speakers are 
banned 32 33% 6 67% 1 17% 25 57% 
Educational dinners are 
banned 33 34% 1 11% 2 33% 30 68% 
I am prohibited from 
attending presentations 
given by PR 
29 30% 3 33% 1 17% 25 57% 





Complete ban: I am 
allowed no contact with 
DMR 
5 9% 0 0% 1 20% 4 9% 
Promotional are speakers 
banned 25 45% 4 67% 2 40% 19 44% 
Educational dinners are 
banned 22 40% 1 17% 1 20% 20 47% 
I am prohibited from 
attending presentations 
delivered by DMR 
16 29% 2 33% 1 20% 13 30% 
Other/ Not sure 28 51% 2 33% 2 40% 24 56% 
PR=Pharmaceutical Representatives  
DMR=Device Manufacturer Representatives 






























































94% 3% 4% 




14% 73% 13% 




7% 83% 10% 




13% 78% 9% 




8% 82% 10% 






35% 50% 15% 






38% 43% 19% 
Current regulations 
on the interaction 
with PR hurt 
physician 
education 
44% 34% 22% 
Current regulations 
on the interaction 
with DMR hurt 
physician 
education 
42% 31% 27% 
Discussions with 
PR have no impact 
on my prescribing 
behavior 
52% 32% 16% 
Discussions with 
DMR have no 
impact on my use 
of surgical devices 
44% 43% 13% 
Acceptance of 
promotional items 
from PR has no 
impact on my 
prescribing 
behavior 
73% 15% 12% 
Acceptance of 
promotional items 
from DMR has no 
impact on which 
surgical device I 
use 







be made public 
online 




from DMR should 
be made public 
online 
50% 31% 19% 
should be banned 
from the OR 
2% 92% 6% 
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In our survey cohort, most respondents (80%) believed that physicians 
could be compromised by gifts in excess of 50USD. 43% of respondents 
had either an ill-defined idea or no awareness at all of the limits their 
institution places on contact with pharmaceutical representatives, with a 
comparable 51% lacking awareness of policies regarding device 
manufacturer representatives. Most respondents viewed industry reps 
as performing important educational functions. 73% believe that 
acceptance of promotional items from pharmaceutical reps has no 
impact on their personal prescribing behaviors, versus 15% of clinicians 
who believe that receipt of promo items from reps does impact clinical 
decisions. Respondents were split on that same measure regarding 
promo items from device reps, with 44% perceiving an impact and 43% 
perceiving no impact. Regarding free-text responses, comments 
included suggestions for syntax and stylistic changes, as well as calls to 
clarify various items on the questionnaire to better elucidate distinctions 












This pilot survey replicates well known research on clinician-industry 
contact. Urologists are generally comfortable interacting with industry 
representatives, and most feel that maintaining a relationship with 
industry is important to both patient care and physician education. 
Importantly, there persists an erroneous belief that contact with 
industry representatives does not impact clinical decision-making. 
Based on free-text feedback from the original survey, future iterations 
will expand and clarify options for institutional limits on 
contact/involvement with industry, and various opinion questions will 
















OPINIONS ON DMR 





DMR should be banned from
the OR
Discussions with DMR have no
impact on my use of surgical
devices
Acceptance of promotional
items from DMR has no impact

















Complete ban: I am allowed no contact with PR, 27% 
Promotional PR speakers are banned, 33% 
Educational dinners from PR are banned, 34% 
I am prohibited from attending presentations given by PR, 30% 
Other/ Not sure what the PR restrictions are, 43% 
Complete ban: I am allowed no contact with DMR, 9% 
Promotional  DMR speakers are banned, 45% 
I am prohibited from attending presentations delivered by DMR, 
29% 
 Other/ Not sure what the DMR restrictions are, 51% 
 
Educational dinners from DMR are banned, 40% 
 
